NASDAQ:PRPO - Nasdaq - US74019L6020 - Common Stock - Currency: USD
NASDAQ:PRPO (5/12/2025, 2:18:55 PM)
6.29
-0.34 (-5.13%)
The current stock price of PRPO is 6.29 USD. In the past month the price increased by 22.77%. In the past year, price increased by 9.85%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 11.34 | 84.86B | ||
CVS | CVS HEALTH CORP | 10.01 | 80.38B | ||
LH | LABCORP HOLDINGS INC | 16.92 | 20.87B | ||
DGX | QUEST DIAGNOSTICS INC | 19.05 | 19.55B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 17.65 | 16.47B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 125.71 | 13.64B | ||
HIMS | HIMS & HERS HEALTH INC | 79.94 | 12.34B | ||
DVA | DAVITA INC | 15.18 | 11.09B | ||
CHE | CHEMED CORP | 24.21 | 8.35B | ||
CRVL | CORVEL CORP | 27.32 | 5.86B | ||
OPCH | OPTION CARE HEALTH INC | 23.37 | 5.20B | ||
GH | GUARDANT HEALTH INC | N/A | 5.11B |
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 54 full-time employees. The company went IPO on 2000-07-18. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
PRECIPIO INC
4 Science Park
New Haven CONNECTICUT 06511 US
CEO: Ilan Danieli
Employees: 54
Phone: 12037877888
The current stock price of PRPO is 6.29 USD. The price decreased by -5.13% in the last trading session.
The exchange symbol of PRECIPIO INC is PRPO and it is listed on the Nasdaq exchange.
PRPO stock is listed on the Nasdaq exchange.
PRECIPIO INC (PRPO) has a market capitalization of 9.44M USD. This makes PRPO a Nano Cap stock.
PRECIPIO INC (PRPO) currently has 54 employees.
PRECIPIO INC (PRPO) has a support level at 6.4 and a resistance level at 6.99. Check the full technical report for a detailed analysis of PRPO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PRPO does not pay a dividend.
PRECIPIO INC (PRPO) will report earnings on 2025-05-12.
PRECIPIO INC (PRPO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.96).
The outstanding short interest for PRECIPIO INC (PRPO) is 1.55% of its float. Check the ownership tab for more information on the PRPO short interest.
ChartMill assigns a technical rating of 5 / 10 to PRPO. When comparing the yearly performance of all stocks, PRPO is one of the better performing stocks in the market, outperforming 76.56% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to PRPO. Both the profitability and financial health of PRPO have multiple concerns.
Over the last trailing twelve months PRPO reported a non-GAAP Earnings per Share(EPS) of -2.96. The EPS increased by 39.32% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -25.24% | ||
ROE | -35.47% | ||
Debt/Equity | 0.04 |
ChartMill assigns a Buy % Consensus number of 83% to PRPO. The Buy consensus is the average rating of analysts ratings from 7 analysts.